Steroidal saponins from Trillium tschonoskii rhizomes and their cytotoxicity against HepG2 cells

Publication date: Available online 23 January 2020Source: SteroidsAuthor(s): Yin-Jun Yang, Xu Pang, Bei Wang, Jie Yang, Xiao-Juan Chen, Xin-Guang Sun, Qi Li, Jie Zhang, Bao-Lin Guo, Bai-ping MaAbstractA phytochemical study on the rhizomes of Trillium tschonoskii led to the isolation of fourteen new steroidal saponins, trillitschosides S1-S14 (1–14), along with ten known analogues (15-24). Their structures were established mainly by spectroscopic analyses as well as necessary chemical evidence. All isolated compounds were screened for the cytotoxicity against HepG2 cells, and the results demonstrated that only the known compounds 21-24 exhibited the remarkable cytotoxic activity against HepG2 cells which is much better than the positive control of 5-FU.Graphical abstractA phytochemical study on the rhizomes of Trillium tschonoskii led to the isolation of fourteen new steroidal saponins (1-14), along with ten known analogues (15-24).
Source: Steroids - Category: Drugs & Pharmacology Source Type: research

Related Links:

AbstractBackgroundPrevious studies have identified that patients withEGFR mutations tend to have better responses to targeted therapy, as well as chemotherapy; however, the effect of genetic alterations in terms of radiotherapy (RT) ‐related outcomes has not been fully assessed. We studied the impact of common non‐small cell lung cancer (NSCLC) genetic alterations (EGFR,ALK andKRAS) in relation to objective response rate (ORR) to RT in patients with brain metastases.MethodsFrom 2009 –2015, 153 patients with an available genotyping status were treated with whole‐brain irradiation (WBI) before receiving systemic ...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
ConclusionsEndostar delivered by CIV with CCRT may be a better option than IV in terms of potential survival and safety for unresectable stage III NSCLC.Key pointsSignificant findings of the study Endostar delivered by continuous intravenous pumping might achieve more favorable survival over intravenous injection and reduce adverse hematological reactions in patients with unresectable stage III NSCLC treated with Endostar combined with CCRT.What this study adds The administration route of recombinant human endostatin is also one key factor for survival and safety to consider when treating patients with unresectable stage III NSCLC.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
ConclusionsThe use of osimertinib immediately after nivolumab significantly increased the frequency of grade 3 or higher hepatotoxicity in patients with advanced NSCLC harboringEGFR mutation acquired T790M resistance.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Authors: Dietrich DE, Bode L, Spannhuth CW, Hecker H, Ludwig H, Emrich HM Abstract BACKGROUND: Whether Borna disease virus (BDV-1) is a human pathogen remained controversial until recent encephalitis cases showed BDV-1 infection could even be deadly. This called to mind previous evidence for an infectious contribution of BDV-1 to mental disorders. Pilot open trials suggested that BDV-1 infected depressed patients benefitted from antiviral therapy with a licensed drug (amantadine) which also tested sensitive in vitro. Here, we designed a double-blind placebo-controlled randomized clinical trial (RCT) which cross-lin...
Source: BMC Pharmacology and Toxicology - Category: Drugs & Pharmacology Tags: BMC Pharmacol Toxicol Source Type: research
Date: Friday, 02 28, 2020; Speaker: Jonathan Wasserman, Staff Physician, SickKids; BG 10-CRC; FAES 1&2
Source: NIH Calendar of Events - Category: American Health Source Type: events
Date: Tuesday, 03 03, 2020; Speaker: TBD, TBD; Dr. Jeremy Veenstra-VanderWeele, Columbia University; Building: Building 10 (Clinical Center); Lipsett Auditorium; CME Credit
Source: NIH Calendar of Events - Category: American Health Source Type: events
Date: Tuesday, 03 10, 2020; Speaker: TBD, TBD; Dr. Jeff Elias, University of Virginia School of Medicine; Building: Building 10 (Clinical Center); Lipsett Auditorium; CME Credit
Source: NIH Calendar of Events - Category: American Health Source Type: events
Date: Tuesday, 03 10, 2020; Speaker: Staff NIH Library; Building: Building 10 (Clinical Center); NIH Library Training Room
Source: NIH Calendar of Events - Category: American Health Source Type: events
Date: Wednesday, 03 11, 2020; Speaker: Staff NIH Library; Building: Building 10 (Clinical Center); This class is presented as a webinar only; Videocast Event
Source: NIH Calendar of Events - Category: American Health Source Type: events
Date: Thursday, 03 12, 2020; Speaker: BTRIS instructor; Building: Building 10 (Clinical Center); NIH Library Training Room
Source: NIH Calendar of Events - Category: American Health Source Type: events
More News: Chemistry | Drugs & Pharmacology | Study